Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Signifor“
Suchtreffer
Begriffe & Kennungen
Signifor · 4.5 · Bradycardic medicinal products Clinical monitoring of heart rate, notably at the beginning of treatment, is re
Eintrag öffnenSignifor · 4.5 · Insulin and antidiabetic medicinal products Dose adjustments (decrease or increase) of insulin and antidiabeti
Eintrag öffnenSignifor · 4.5 · Insulin and antidiabetic medicinal products Dose adjustments (decrease or increase) of insulin and antidiabeti
Eintrag öffnenSignifor · 4.5 · Medicinal products that prolong the QT interval Pasireotide should be used with caution in patients who are co
Eintrag öffnenSignifor · 4.5 · Medicinal products that prolong the QT interval Pasireotide should be used with caution in patients who are co
Eintrag öffnenSignifor · 4.5 · Pasireotide may decrease the relative bioavailability of ciclosporin. Concomitant administration of pasireotid
Eintrag öffnenSignifor · 4.5 · Pasireotide may decrease the relative bioavailability of ciclosporin. Concomitant administration of pasireotid
Eintrag öffnenSignifor · 4.5 · The influence of the P-gp inhibitor verapamil on the pharmacokinetics of subcutaneous pasireotide was tested i
Eintrag öffnenSignifor · 4.5 · The influence of the P-gp inhibitor verapamil on the pharmacokinetics of subcutaneous pasireotide was tested i
Eintrag öffnenSignifor · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenSignifor · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenSignifor · 4.8 Undesirable effects · 1
Eintrag öffnenSignifor · 4.8 Undesirable effects · 2
Eintrag öffnenSignifor · 4.8 · 22 Table 1 Adverse reactions by preferred term for pasireotide intramuscular use
Eintrag öffnenSignifor · 4.8 · 23 Description of selected adverse reactions
Eintrag öffnenSignifor · 4.8 · 24 Injection site reactions In the phase III studies, injection site related reactions (e.g. injection site pa
Eintrag öffnenSignifor · 4.8 · 7 Table 1 Adverse reactions in the phase III study and from post-marketing experience in Cushing’s disease pat
Eintrag öffnenSignifor · 4.8 · 8 Description of selected adverse reactions
Eintrag öffnenSignifor · 4.8 · A total of 201 Cushing’s disease patients received Signifor in phase II and III studies. The safety profile of
Eintrag öffnenSignifor · 4.8 · Acromegaly In acromegaly, the safety assessment was made based on 491 patients who received pasireotide (419 p
Eintrag öffnen